Literature DB >> 28945897

Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.

Miriam A Bredella1, Melanie Schorr2, Laura E Dichtel2, Anu V Gerweck2, Brian J Young2, Whitney W Woodmansee3, Brooke Swearingen4, Karen K Miller2.   

Abstract

Context: Acromegaly is characterized by growth hormone (GH) and insulinlike growth factor-1 (IGF-1) hypersecretion, and GH and IGF-1 play important roles in regulating body composition and glucose homeostasis. Objective: The purpose of our study was to investigate body composition including ectopic lipids, measures of glucose homeostasis, and gonadal steroids in patients with active acromegaly compared with age-, body mass index (BMI)-, and sex-matched controls and to determine changes in these parameters after biochemical control of acromegaly. Design: Cross-sectional study of 20 patients with active acromegaly and 20 healthy matched controls. Prospective study of 16 patients before and after biochemical control of acromegaly. Main Outcome Measures: Body composition including ectopic lipids by magnetic resonance imaging/proton magnetic resonance spectroscopy; measures of glucose homeostasis by an oral glucose tolerance test; gonadal steroids.
Results: Patients with active acromegaly had lower mean intrahepatic lipid (IHL) and higher mean fasting insulin and insulin area under the curve (AUC) values than controls. Men with acromegaly had lower mean total testosterone, sex hormone-binding globulin, and estradiol values than male controls. After therapy, homeostasis model assessment of insulin resistance, fasting insulin level, and insulin AUC decreased despite an increase in IHL and abdominal and thigh adipose tissues and a decrease in muscle mass. Conclusions: Patients with acromegaly were characterized by insulin resistance and hyperinsulinemia but lower IHL compared with age-, BMI-, and sex-matched healthy controls. Biochemical control of acromegaly improved insulin resistance but led to a less favorable anthropometric phenotype with increased IHL and abdominal adiposity and decreased muscle mass.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28945897      PMCID: PMC6283448          DOI: 10.1210/jc.2017-01210

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women.

Authors:  M Gambacciani; M Ciaponi; B Cappagli; L Piaggesi; L De Simone; R Orlandi; A R Genazzani
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

2.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

3.  Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study.

Authors:  R K Stellato; H A Feldman; O Hamdy; E S Horton; J B McKinlay
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

4.  Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.

Authors:  Michael Madsen; Thomas Krusenstjerna-Hafstrøm; Louise Møller; Britt Christensen; Mikkel Holm Vendelbo; Steen B Pedersen; Jan Frystyk; Niels Jessen; Troels Krarup Hansen; Hans Stødkilde-Jørgensen; Allan Flyvbjerg; Jens Otto L Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2012-02-01       Impact factor: 5.958

5.  Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women.

Authors:  H Nørrelund; J Børglum; J O Jørgensen; B Richelsen; N Møller; K S Nair; J S Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

6.  Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.

Authors:  Miriam A Bredella; Anu V Gerweck; Eleanor Lin; Melissa G Landa; Martin Torriani; David A Schoenfeld; Linda C Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

7.  Breath-hold 1H-magnetic resonance spectroscopy for intrahepatic lipid quantification at 3 Tesla.

Authors:  Miriam A Bredella; Reza Hosseini Ghomi; Bijoy J Thomas; Hugue A Ouellette; Dushyant V Sahani; Karen K Miller; Martin Torriani
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

8.  Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

Authors:  Gemma Sesmilo; Wesley P Fairfield; Laurence Katznelson; Karen Pulaski; Pamela U Freda; Vivien Bonert; Eleni Dimaraki; Stavros Stavrou; Mary Lee Vance; Douglas Hayden; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 9.  Nonalcoholic fatty liver disease.

Authors:  Andy S Yu; Emmet B Keeffe
Journal:  Rev Gastroenterol Disord       Date:  2002

10.  Endogenous Androgens and Sex Hormone-Binding Globulin in Women and Risk of Metabolic Syndrome and Type 2 Diabetes.

Authors:  Benjamin Fenske; Hanna Kische; Stefan Gross; Henri Wallaschofski; Henry Völzke; Marcus Dörr; Matthias Nauck; Brian G Keevil; Georg Brabant; Robin Haring
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

View more
  12 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.

Authors:  Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer
Journal:  JCI Insight       Date:  2020-03-12

3.  The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.

Authors:  Laura E Dichtel; Kathleen E Corey; Melanie S Haines; Mark L Chicote; Allison Kimball; Caitlin Colling; Tracey G Simon; Michelle T Long; Jad Husseini; Miriam A Bredella; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

Review 4.  Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system.

Authors:  Omar Al-Massadi; Paolo Parini; Johan Fernø; Serge Luquet; Mar Quiñones
Journal:  Rev Endocr Metab Disord       Date:  2022-06-10       Impact factor: 9.306

Review 5.  Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Authors:  Laura E Dichtel; Jose Cordoba-Chacon; Rhonda D Kineman
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

6.  Semen quality in hypogonadal acromegalic patients.

Authors:  Mikkel Andreassen; Anders Juul; Ulla Feldt-Rasmussen; Niels Jørgensen
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

7.  Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly.

Authors:  Tao Xie; Hailin Ding; Mingfeng Xia; Xiaobiao Zhang; Wei Sun; Tengfei Liu; Ye Gu; Chongjing Sun; Fan Hu
Journal:  Endocrine       Date:  2018-09-10       Impact factor: 3.633

Review 8.  Insulin Resistance in Patients With Acromegaly.

Authors:  Greisa Vila; Jens Otto L Jørgensen; Anton Luger; Günter K Stalla
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-30       Impact factor: 5.555

9.  Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study.

Authors:  Hélène Lasolle; Amandine Ferriere; Alexandre Vasiljevic; Sandrine Eimer; Marie-Laure Nunes; Antoine Tabarin
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

10.  Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly.

Authors:  Adriana P Kuker; Wei Shen; Zhezhen Jin; Simran Singh; Jun Chen; Jeffrey N Bruce; Pamela U Freda
Journal:  J Endocr Soc       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.